Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing 530% to $0.63. Despite modest 2025 guidance, Pfizer's oncology and anti-obesity drugs present growth potential, countering analysts' low expectations. However, risks remain, which include political challenges and patent expirations.
Pfizer's CEO said he may move manufacturing back to the US in response to Donald Trump's tariffs. Albert Bourla said he was not surprised by Trump's victory in November.
Pfizer Inc. (NYSE:PFE ) TD Cowen 45th Annual Health Care Conference March 3, 2025 10:30 AM ET Company Participants Albert Bourla - Chairman and CEO Conference Call Participants Steve Scala - TD Cowen Steve Scala Well, good morning once again, and welcome to TD Cowen's 45th Annual Healthcare Conference. We are absolutely delighted to have Pfizer with us again this year.
Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to the U.S., if required, as President Donald Trump's administration threatens numerous tariffs on imported goods.
Buying low to sell later when the stock's price is high is a time-honored investing strategy. With the benchmark S&P 500 index near its all-time high, though, now might seem like the wrong time to go looking for stocks that trade at bargain prices.
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields about 3...
A meeting of the Food and Drug Administration's vaccine advisory committee to discuss the next season's flu vaccine has reportedly been canceled, the second such disruption of a meeting involving vaccine policy experts at the federal level since prominent vaccine skeptic Robert F. Kennedy Jr took over as the Health and Human Services secretary earlier this month.
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.